It suggests that there are still other mechanisms for right ventricular remodeling and occurrence and development of heart failure. Surprisingly, classic drugs that inhibit left ventricular remodeling and left heart failure cannot effectively improve or reverse the right ventricular function and improve the survival rate in PAH patients.
At present, the clinical understanding of right ventricular remodeling mechanism and drug therapy is mainly derived from the left ventricle. Therefore, it is of great clinical significance to maintain effective right ventricular structure and function. Clinical studies have confirmed that different patients show significantly different right ventricular adaptive response and clinical prognosis in response to the same pulmonary vascular resistance. The functional state of the right ventricle is an independent predictor of clinical symptoms and survival prognosis. Current studies have shown that the degree of increased pulmonary artery pressure is only moderately correlated with clinical prognosis. Despite the improvement of modern drugs and treatment methods, the prognosis of PAH patients is still poor, and the annual mortality rate of 2.5% for females and 0.9% for males has been maintained in the past ten years. The prevalence rate of PAH of all kinds has exceeded 30~50 per 1 million people, making it one of the most important diseases endangering human beings. Subsequently, it leads to a clinicopathological syndrome characterized by right ventricular remodeling and right heart failure. Pulmonary arterial hypertension (PAH) is determined by alterations of pulmonary vascular function and structure caused by a variety of factors, leading to a progressive increase in pulmonary vascular resistance.
0 kommentar(er)
